1 / 16

Title, date Mr. Einar Magnússon Director, Department of Pharmaceutical Affairs

Title, date Mr. Einar Magnússon Director, Department of Pharmaceutical Affairs Ministry for Health. Overview of this presentation. The Pharmaceutical Act No. 93/1994 – a framework and legal base Technical regulations Implementation of directives Questions on Medicinal Products

virginie-michel
Download Presentation

Title, date Mr. Einar Magnússon Director, Department of Pharmaceutical Affairs

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Title, date Mr. Einar Magnússon Director, Department of Pharmaceutical Affairs Ministry for Health

  2. Overview of this presentation • The Pharmaceutical Act No. 93/1994 – a framework and legal base • Technical regulations • Implementation of directives • Questions on Medicinal Products • Problems of the small markets

  3. The Icelandic Pharmaceutical Act No. 93/1994 • The Icelandic Pharmaceutical Act is a framework and legal base for technical regulations • In particular article no. 49 of the act has been useful as a legal base for issuing and publication of EC regulations and directives • The Pharmaceutical Act has been changed 29 times since 1994 • The structure of the act needs to be revised, some things need to be clarified and some things are missing in particular some definitions. • The implementation of the pharmaceutical package from 2004 is ongoing.

  4. Technical regulations on medicinal products • Marketing authorisations, labelling and package leaflets • Advertising • Manufacture • Importation and wholesaling • Parallel import • Herbal medicines • Homeopathic medicinal products • Clinical practice • Pharmacies and pharmacy license • Dose dispensing • Colouring chemicals • Narcotics and psychotropic substances • Pricing and reimbursement • Blood and blood products • Etc.

  5. Questions from the Commision on Medicinal products Trasposition tables – Chapter 1 • Directive 2001/83/EC on the Community code relating to medicinal products for human use • Directive 2001/82/EC on the Community code relating to veterinary medicinal products • Iceland should provide information on how these Directives have been implemented with regards to the authorisation of medicinal products to be placed on the market (marketing authorisation), advertising, manufacture, importation, labelling, whole sale distribution, advertising, pharmacovigilance, supervision and sanctions of medicinal product

  6. Ansvers to Questions from the Commision on Medicinal products Trasposition tables – Chapter 1 • Marketing Authorisation: Regulations concerning marketing authorisations for proprietary medicinal products, their labelling and package leaflets No. 462/2000 and ammandments reg. No. 766/2001, 443/2005, 581/2006, 1251/2008 and 873/2010 • Advertising: Regulation on advertising No. 328/1995 • and amendment No. 95/2001 • Manufacture: Regulation on Manufacture of Medicinal Products No 893/2004 • Importation: Regulation on import and wholesaling No. 699/1996 and amendments No. 484/2001 and No. 846/2002 • Labelling: Regulation No. 462/2000 • Whole sale distribution: Regulation No. 699/1996 • Pharmacovigilance: Regulation No. 462/2000 • Supervision and sanctions of medicinal product: Chapter XVI, article 47 and article 48 of the Pharmaceutical Act No. 93/1994

  7. Regulations concerning marketing authorisations for proprietary medicinal products, their labelling and package leaflets No. 462/2000 and ammandments reg. No. 766/2001, 443/2005, 581/2006, 1251/2008 and 873/2010 • Dir. 2000/38/EC • Dir. 2001/83/EC • Dir. 2001/82/EC • Dir. 2003/63/EC • Regul. 2309/93/EC • Regul. 540/95/EC • Regul. 541/95/EC • Regul. 542/95/EC • Regul. 2141/96/EC • Regul. 649/98/EC • Regul. 1146/98/EC • Regul. 1069/98/EC • Regul. 141/2000/EC • Regul. 847/2000/EC • Regul. 1084/2003/EC • Regul. 1085/2003/EC • Regul. 1647/2003/EC • Regul.273/2004/EC • Regul.1277/2005 • Regul.2049/2005/EC • Regul.1950/2006/EC • Regul.1394/2007/EC • Regul. 1234/2008/EC

  8. Revised regulation for MA´s will be issued in December 2010 • Dir. 2004/27/EC • Dir. 2004/28/EC • (Regul. 726/2004/EC)

  9. Regulation on advertising No. 328/1995 and amendment No. 95/2001 • Dir. 2001/83/EC

  10. Regulations on import and wholesaling • Regulation on import and wholesaling No. 699/1996 and amendments No. 484/2001 and No. 846/2002 • Dir. 2001/83/EC • Dir. 2001/82/EC • Regulation on import of medicinal products for personal use No. 212/1998 and amendment No. 230/2001 • Dir. 2001/83/EC • Regulation on import of homeopathic medicinal products No. • Dir. 2001/83/EC • Dir. 2001/82/EC

  11. Questions on Medicinal products – Trasposition tables – Chapter 1 • Iceland should provide information on how the following Directives have been implemented • Commission Directive 2003/94/EC and Commission Directive 91/412/EEC on good manufacturing practice • Directive 2001/20/EC of the European Parliament and of the Council and Commission Directive 2005/28/EC relating to good clinical practice

  12. Regulation on Manufacture of Medicinal Products No 893/2004 • Dir. 2001/83/EC • Dir. 2001/82/EC • Dir. 91/412/EC • Dir. 2003/94/EC • Dir. 2001/20/EC

  13. Regulation on Manufacture of Medicinal Products No 893/2004 Revised regulation will be issued in Dcember 2010 • Dir. 2005/28/EC

  14. Regulation on clinical trials No. 443/2004 and amendment No. 907/2004 • Dir. 2001/83/EC • Dir. 2001/20/EC

  15. Regulation on clinical trials No. 443/2004 Revised regulation will be issued in December 2010 • Commission Directive 2005/28/EC relating to good clinical practice

  16. Problems of the small markets • Common for the small markets (countries with less than 2 m inhabitants) is less access to medicines than on bigger markets and higher prices. • The language requirement can in many cases be a barrier for the market in particular for low volume medicines. • With a reference to Belgium-Luxemburg Iceland wants to take up the possibility to be closer connected to a bigger market concerning marketing authorisations.

More Related